Brickell Financial Statements From 2010 to 2022

BBI
 Stock
  

USD 4.07  0.30  7.96%   

Brickell Biotech financial statements provide useful quarterly and yearly information to potential Brickell Biotech investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Brickell Biotech financial statements helps investors assess Brickell Biotech's valuation, profitability, and current liquidity needs.
We have found ninety-eight available fundamental signals for Brickell Biotech, which can be analyzed and compared to other ratios and to its rivals. Please verify all of Brickell Biotech prevailing fundamental drivers against the trend between 2010 and 2022 to make sure the company can sustain itself down the road.
Brickell Biotech Average Equity is most likely to decrease significantly in the upcoming years. The last year's value of Average Equity was reported at 24.09 Million. The current Enterprise Value is estimated to increase to about 5.1 M, while Net Income Per Employee is projected to decrease to (1.9 M).
  
Check Brickell Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Brickell main balance sheet or income statement drivers, such as Direct Expenses of 1.7 M, Cost of Revenue of 7.3 M or Gross Profit of 414.6 K, as well as many exotic indicators such as PPandE Turnover of 4.69, Accounts Payable Turnover of 2.36 or Accrued Expenses Turnover of 0.54. Brickell financial statements analysis is a perfect complement when working with Brickell Biotech Valuation or Volatility modules. It can also supplement various Brickell Biotech Technical models . Continue to the analysis of Brickell Biotech Correlation against competitors.

Brickell Biotech Revenues

414,632

Brickell Biotech Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets37.2 M29.7 M51.4 M
Decreasing
Slightly volatile
Cash and Equivalents24.7 M26.9 M26.3 M
Decreasing
Slightly volatile
Investments4.2 MM17.4 M
Decreasing
Slightly volatile
Investments Current5.3 M5.2 M15.7 M
Decreasing
Slightly volatile
Investments Non Current2.2 MM2.7 M
Decreasing
Slightly volatile
Deferred RevenueM2.1 M2.6 M
Increasing
Slightly volatile
Property Plant and Equipment Net120.1 K117 K2.2 M
Decreasing
Slightly volatile
Trade and Non Trade Receivables5.3 M5.9 M4.4 M
Increasing
Slightly volatile
Trade and Non Trade Payables2.5 M1.6 M3.9 M
Decreasing
Slightly volatile
Goodwill and Intangible Assets407.3 K396.9 K1.3 M
Decreasing
Slightly volatile
Total Liabilities4.9 M4.8 M8.7 M
Increasing
Very volatile
Shareholders Equity28.6 M24.9 M38 M
Decreasing
Slightly volatile
Accumulated Other Comprehensive Income(25.9 K)(25.2 K)112.1 K
Decreasing
Slightly volatile
Current Assets35 M29.6 M45.8 M
Decreasing
Slightly volatile
Assets Non Current120.1 K117 K5.5 M
Decreasing
Slightly volatile
Current Liabilities7.3 M4.8 M8.1 M
Increasing
Stable
Liabilities Non Current134.9 K131.4 K1.1 M
Decreasing
Slightly volatile
Total Debt403.6 K393.3 K3.3 M
Decreasing
Slightly volatile
Debt Current268.8 K261.9 K3.3 M
Decreasing
Slightly volatile
Debt Non Current151.8 K167.9 K92 K
Increasing
Slightly volatile
Shareholders Equity USD28.6 M24.9 M38 M
Decreasing
Slightly volatile
Cash and Equivalents USD24.7 M26.9 M26.3 M
Decreasing
Slightly volatile
Total Debt USD403.6 K393.3 K3.3 M
Decreasing
Slightly volatile
Accounts Payable2.2 MMM
Increasing
Slightly volatile

Brickell Biotech Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues414.6 K404 K13.2 M
Decreasing
Slightly volatile
Cost of Revenue7.3 M5.8 M8.7 M
Decreasing
Slightly volatile
Selling General and Administrative Expense12.1 M12.4 M9.8 M
Increasing
Stable
Research and Development Expense23.8 M28.2 M16.3 M
Increasing
Slightly volatile
Operating Expenses35.9 M40.6 M26.1 M
Increasing
Slightly volatile
Interest Expense63.7 K62.1 K930.8 K
Decreasing
Slightly volatile
Preferred Dividends Income Statement Impact(9.5 M)(9.2 M)1.1 M
Decreasing
Slightly volatile
Weighted Average Shares1.9 M1.8 M351.2 K
Increasing
Slightly volatile
Weighted Average Shares Diluted1.9 M1.8 M351.2 K
Increasing
Slightly volatile
Revenues USD414.6 K404 K13.2 M
Decreasing
Slightly volatile
Gross Profit414.6 K404 KM
Decreasing
Slightly volatile
Direct Expenses1.7 M1.7 M6.9 M
Decreasing
Slightly volatile

Brickell Biotech Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow Business Acquisitions and Disposals11.6 M11.7 M12.8 M
Decreasing
Slightly volatile
Net Cash Flow Investment Acquisitions and Disposals5.6 M5.2 M1.6 M
Increasing
Slightly volatile
Net Cash Flow from Financing35.6 M33 M15.4 M
Increasing
Slightly volatile
Issuance Repayment of Debt Securities 591.4 K502.6 K(605.2 K)
Increasing
Slightly volatile
Issuance Purchase of Equity Shares35.6 M33 M15.3 M
Increasing
Slightly volatile
Net Cash Flow from Investing(36.9 K)(36 K)(30.8 K)
Increasing
Slightly volatile
Net Cash Flow from Operations(37.1 M)(36.1 M)(16.4 M)
Decreasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents(3.3 M)(3.2 M)(1.2 M)
Increasing
Slightly volatile
Share Based Compensation2.1 M2.3 M2.2 M
Decreasing
Slightly volatile
Depreciation Amortization and Accretion22.6 K22 K1.1 M
Decreasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Return on Invested Capital16.6515.4333.2454
Increasing
Slightly volatile
Gross Margin0.931.150.6056
Increasing
Slightly volatile
Asset Turnover0.01330.0130.225
Decreasing
Slightly volatile
Sales per Share0.230.226504
Decreasing
Slightly volatile
Price to Sales Ratio49.145.50612.7738
Increasing
Slightly volatile
Price to Book Value1.211.0571.8123
Decreasing
Slightly volatile
Debt to Equity Ratio0.230.1930.2179
Increasing
Stable
Current Ratio6.476.1547.6276
Decreasing
Slightly volatile
Free Cash Flow per Share(21.88)(20.274)(267)
Increasing
Slightly volatile
Book Value per Share14.3213.955911
Decreasing
Slightly volatile
Tangible Assets Book Value per Share17.0916.651.5 K
Decreasing
Slightly volatile
Total Assets Per Share2.532.4633.7123
Decreasing
Slightly volatile
PPandE Turnover4.694.145.514
Increasing
Stable
Cash and Equivalents Turnover0.08160.07950.4781
Decreasing
Stable
Accounts Payable Turnover2.362.321.6235
Decreasing
Slightly volatile
Accrued Expenses Turnover0.540.522.348
Decreasing
Slightly volatile
Quick Ratio0.460.455.5029
Decreasing
Slightly volatile
Net Current Assets as percentage of Total Assets67.9147.3669.1445
Decreasing
Slightly volatile
Revenue to Assets0.310.390.2761
Increasing
Slightly volatile

Brickell Biotech Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Capitalization27 M26.3 M100 M
Decreasing
Slightly volatile
Enterprise Value5.1 MM74 M
Decreasing
Slightly volatile
Invested Capital(2 M)(2 M)15.7 M
Decreasing
Slightly volatile
Average Equity32.3 M24.1 M46.4 M
Decreasing
Slightly volatile
Average Assets39.2 M30.5 M54.7 M
Decreasing
Slightly volatile
Invested Capital Average(2.6 M)(2.6 M)20.3 M
Decreasing
Slightly volatile
Tangible Asset Value36.7 M29.7 M50.2 M
Decreasing
Slightly volatile
Free Cash Flow(37.1 M)(36.2 M)(16.6 M)
Decreasing
Slightly volatile
Working Capital29 M24.8 M37.8 M
Decreasing
Slightly volatile
Revenue Per Employee512.5 K475 K278.3 K
Increasing
Slightly volatile

Brickell Fundamental Market Drivers

Short Percent Of Float6.98%
Forward Price Earnings-0.47
Shares Short Prior Month108.4k
Average Daily Volume Last 10 Day413.79k
Average Daily Volume In Three Month262.25k
Date Short Interest15th of July 2022
Fifty Day Average4.8916
Two Hundred Day Average10.5469

Brickell Upcoming Events

Upcoming Quarterly Report8th of March 2022
Next Financial Report12th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End8th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

About Brickell Biotech Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Brickell Biotech income statement, its balance sheet, and the statement of cash flows. Brickell Biotech investors use historical funamental indicators, such as Brickell Biotech's revenue or net income, to determine how well the company is positioned to perform in the future. Although Brickell Biotech investors may use each financial statement separately, they are all related. The changes in Brickell Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Brickell Biotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Brickell Biotech Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Brickell Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Deferred Revenue2.1 MM
Cost of Revenue5.8 M7.3 M
Revenues404 K414.6 K
Revenue to Assets 0.39  0.31 
Revenue Per Employee475 K512.5 K
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company was founded in 2009 and is headquartered in Boulder, Colorado. Brickell Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people.

Brickell Biotech Investors Sentiment

The influence of Brickell Biotech's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Brickell. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Brickell Biotech's public news can be used to forecast risks associated with investment in Brickell. The trend in average sentiment can be used to explain how an investor holding Brickell can time the market purely based on public headlines and social activities around Brickell Biotech. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Brickell Biotech's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Brickell Biotech's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Brickell Biotech's news discussions. The higher the estimate score, the more favorable is the investor's outlook on Brickell Biotech.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Brickell Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Brickell Biotech's short interest history, or implied volatility extrapolated from Brickell Biotech options trading.

Pair Trading with Brickell Biotech

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Brickell Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Brickell Biotech will appreciate offsetting losses from the drop in the long position's value.

Moving against Brickell Biotech

0.87ALTAltimmune Earnings Call  This WeekPairCorr
0.83ANNXAnnexon Earnings Call  This WeekPairCorr
0.79ALLOAllogene Therapeutics Earnings Call  TomorrowPairCorr
0.76ADMAAdma Biologics Earnings Call  This WeekPairCorr
The ability to find closely correlated positions to Brickell Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Brickell Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Brickell Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Brickell Biotech to buy it.
The correlation of Brickell Biotech is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Brickell Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Brickell Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Brickell Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to the analysis of Brickell Biotech Correlation against competitors. Note that the Brickell Biotech information on this page should be used as a complementary analysis to other Brickell Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Complementary Tools for Brickell Stock analysis

When running Brickell Biotech price analysis, check to measure Brickell Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brickell Biotech is operating at the current time. Most of Brickell Biotech's value examination focuses on studying past and present price action to predict the probability of Brickell Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brickell Biotech's price. Additionally, you may evaluate how the addition of Brickell Biotech to your portfolios can decrease your overall portfolio volatility.
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Is Brickell Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brickell Biotech. If investors know Brickell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brickell Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
10 M
Quarterly Revenue Growth YOY
4.41
Return On Assets
-0.85
Return On Equity
-1.76
The market value of Brickell Biotech is measured differently than its book value, which is the value of Brickell that is recorded on the company's balance sheet. Investors also form their own opinion of Brickell Biotech's value that differs from its market value or its book value, called intrinsic value, which is Brickell Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brickell Biotech's market value can be influenced by many factors that don't directly affect Brickell Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brickell Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Brickell Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brickell Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.